m-RESIST Newsletter Issue 3 | January 2018
Email not dislpaying correctly? View it in your browser.


Dear readers,

We are very glad to introduce you the 3rd and final newsletter of the m-RESIST project.

Issue 3 focuses on presenting the latest achievements and results of the project. More specifically, you will have the opportunity to read our project news, past events and publications as well as upcoming events. 

Thank you for your interest in our work! Enjoy the reading!
The m-RESIST consortium

What is m-RESIST? A quick overview

The m-RESIST solution is an innovative disease management system based on mobile technologies, addressed to empower patients with treatment-resistant schizophrenia, which will engage them, together with the professionals and caregivers, in active participation in therapeutic processes, enabling them to better self-manage their condition. 

Project News

m-RESIST Solution at a glance

The m-RESIST ecosystem provides patients, caregivers and health professionals the ability to enhance their daily activities through two main interfaces. A mobile app connected to a smartwatch and a web dashboard.


Users'Evaluation Workshop

In November 2017, a workshop with 3 user groups (patients, relatives and health professionals) was carried out at Parc Sanitari Sant Joan de Déu aiming to assess the acceptability and usability of the m-RESIST solution and the tools included. Different results were obtained by the workshop.


m-RESIST Final workshop

The m-RESIST Final workshop was held in Sant Pau Recinte Modernista, Barcelona, Spain, on November 30th, 2017. Apart from disseminating and presenting the preliminary results of the m-RESIST project team, the workshop aimed to creating a participatory environment so that attendees could contribute with feedback on the project.


Lessons Learned

Our multi-institutional/multi-disciplinary team has learned 3 key lessons conducting the m-RESIST project. We summarize them aiming to inform and prepare researchers who are planning an mHealth study.


m-RESIST video

Want to learn more about the m-RESIST Solution? Check out the video below!
m-RESIST An innovative disease management system based on mobile technologies
m-RESIST An innovative disease management system based on mobile technologies

Did you know that?

m-RESIST Consortium has published several articles in scientific journals and has been presented in several events, succeeding in raising the awareness of the project to various interested parties.

Latest Publications
On September 14th, 2017, Matti Isohanni (OULU) and Eva Grasa (IR-HSCSP), chaired the Symposium “Optimizing the path to recovery in treatment-resistant and difficult-to treat schizophrenia: Challenges and alternatives”, during the 6th European Conference on Schizophrenia Research (ECSR 2017), held in Berlin, Germany. During the symposium the following presentations took place:
  • "Treatment-resistant and difficult-to treat schizophrenia as a challenge for clinical practices. Data from Finnish samples: Northern Finland birth cohort 1966 and Perfect project", Jussi Seppälä (OULU)
  • “Predictors of response in treatment-resistant schizophrenia: a meta-analysis", Annika Seppälä (OULU)
  • "Predictors of functioning improvement in difficult-to-treat schizophrenia", Kinga Farkas (SEMMELWEIS)
  • "mRESIST, an innovative m-health tool addressed to improve humanistic burden in difficult-to-treat schizophrenia”, Illuminada Corripio (IR-HSCSP)
On October 5th, 2017 Illuminada Corripio (IR-HSCSP) gave the presentation “Wearable Computing Solutions” at the IOT Solutions World Congress, held in Barcelona, Spain.
In addition, m-RESIST was presented at the eHealth Forum 2017 Exhibition that took place in Technopolis City of Athens, Athens, Greece, from 20th to 22nd October 2017. ATC participated with a booth there and showcased m-RESIST latest developments but also other H2020 research projects (City4Age, BD2Decide and EVOTION), all EU-funded within the wider scope of the digital transformation of health area.
Furthermore, on October 26th -27th, 2017, Silvia Marcó-García (PSSJD) presented the poster about “Gender Differences in Carers of Patients with Schizophrenia: a qualitative study”, at the II European Meeting on Women's Mental Health, held in Barcelona, Spain. At the same time IR-HSCSP presented the poster “Mobile therapeutic attention for patients with treatment-resistant schizophrenia – m-RESIST” at the Annual Assembly ITEMAS 2017, held in Santander, Spain.

On December 14th, 2017,  IMEC presented the paper “Changing Behaviour in the Digital Era - A Concrete Use Case from the Domain of Health”, at the 19th International Conference on Behaviour Change (ICBC 2017), held in Barcelona, Spain.

Where to look next!

  1. m-RESIST will be presented at the National Congress of the Hungarian Psychiatric Association to be held in Debrecen, Hungary from 24 - 27 January 2018. Semmelweis team will organise there a symposium “E-health és szkizofrénia” that will be chaired by Unoka Zsolt and will include four presentations by m-RESIST members.
  2. On April 4th-8th, 2018, Susanna Ochoa (PSSJD) will present the poster about “User Experience towards an Integral Intervention Model Based on M-Health Solution for Patients with Treatment-Resistant Schizophrenia (m-RESIST): Qualitative Information from patients, Caregivers and Clinicians in a Pilot Study,” at the Schizophrenia International Research Society Conference (SIRS 2018) to be held in Florence, Italy

Who are we?

Contact information
Project coordinator
Margarita Hospedales Salomo, FUNDACIO TICSALUT (Spain)


Do you want to be part of it or know about it?

Copyright © 2018 m-RESIST - All rights reserved.

This project is co-funded by the Horizon 2020 Framework Programme of the European Union under grant agreement no [643552].

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
m-RESIST Project · An EU-Funded project by H2020 programme · Mobile Therapeutic Attention for patients with Treatment Resistant Schizophrenia 643552 · Belgium

Email Marketing Powered by Mailchimp